Sunhydrogen, Inc.: Form 10-Q for the period ended Mar 31, 2023
Filed with the SEC on May 15, 2023 and accepted by EDGAR at May 15, 2023, 16:10 ET.
Management's discussion and analysis
As filed, 14,000 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Cautionary Statement Regarding Forward-Looking Statements
The information in this report may contain forward-looking statements. These forward-looking statements involve risks and uncertainties, including statements regarding our capital needs, business strategy and expectations. Any statements that are not of historical fact may be deemed to be forward-looking statements. These forward-looking statements involve substantial risks and uncertainties. In some cases you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expect,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” or “continue”, the negative of the terms or other comparable terminology. Actual events or results may differ materially from the anticipated results or other expectations expressed in the forward-looking statements. In evaluating these statements, you should consider various factors, including the risks included from time to time in our reports filed with the Securities and Exchange Commission, or the SEC. These factors may cause our actual results to differ materially from any forward-looking statements. We disclaim any obligation to publicly update these statements, or disclose any difference between actual results and those reflected in these statements, except as may be required under applicable law.
Unless the context otherwise requires, references in this Form 10-Q to “we,” “us,” “our,” or the “Company” refer to SunHydrogen, Inc.
Overview
At SunHydrogen, our goal is to replace fossil fuels with clean, renewable hydrogen.
Hydrogen is the most abundant chemical element in the universe. When hydrogen fuel is used to power transportation and industry, the only byproduct left behind is pure water, unlike hydrocarbon fuels such as oil, coal and natural gas that emit carbon dioxide and other harmful pollutants into the atmosphere. However, naturally occurring elemental hydrogen is rare – so rare, in fact, that today about 95% of hydrogen is produced from steam reforming of natural gas (Source: US Department of Energy, Hydrogen Fuel Basics). This process is both economically and environmentally unsound.
The SunHydrogen solution offers an efficient and cost-effective way to produce truly green hydrogen using sunlight and any source of water. Our core technology is a self-contained, nanoparticle-based hydrogen generator that mimics photosynthesis to split water molecules, resulting in hydrogen. By optimizing the science of water electrolysis at the nano-level, we believe we have developed a low-cost method to potentially produce environmentally friendly renewable hydrogen.
We believe renewable hydrogen has already proven itself to be a key solution in helping the world meet climate targets, and we believe our technology potentially offers solutions to the challenges that the hydrogen future presents, including cost of production and transportation.
Because our process only requires sunlight and water, our technology can be installed near the point of hydrogen use. This eliminates the need for pipelines and trucks that result in high carbon emissions and high capital investment. Additionally, because our process directly uses the electrical charges created by sunlight to generate hydrogen, our nanoparticle technology does not rely on grid power or require the costly power electronics that conventional electrolyzers do. Lastly, our planned scalable system configuration of many individual hydrogen-generating panels ensures redundancy, security and stability.
With a target cost of $2.50/kg., we aspire for our technology to be cost-competitive with brown hydrogen and below the cost of clean hydrogen competitors. We believe our solution has the potential to clear a path for green hydrogen to compete with natural gas hydrogen and gain mass market acceptance as a true replacement for fossil fuels.
Our technology is primarily developed at three laboratories – our independent laboratory in Coralville, Iowa, the SunHydrogen laboratory at the University of Iowa, and the Singh laboratory at University of Michigan.
Additionally, in parallel to the ongoing development of our own technology, we are well-capitalized to begin pursuing synergistic strategic investments in the hydrogen space. SunHydrogen is committed to furthering renewable hydrogen technology to grow the hydrogen ecosystem, and we are actively pursuing opportunities for investment and acquisition of complimentary hydrogen technologies. We are fortunate to have the resources to maximize our impact in this fast-growing industry.
Critical Accounting Policies
Our discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to impairment of property, plant and equipment, intangible assets, deferred tax assets and fair value computation using the Binomial valuation option pricing model. We base our estimates on historical experience and on various other assumptions, such as the trading value of our common stock and estimated future undiscounted cash flows, that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions; however, we believe that our estimates, including those for the above-described items, are reasonable.
Use of Estimates
In accordance with accounting principles generally accepted in the United States, management utilizes estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. These estimates and assumptions relate to useful lives and impairment of tangible and intangible assets, accruals, income taxes, stock-based compensation expense, Binomial lattice valuation model inputs, derivative liabilities and other factors. Management believes it has exercised reasonable judgment in deriving these estimates. Consequently, a change in conditions could affect these estimates.
Fair Value of Financial Instruments
Fair value of financial instruments requires disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value. As of March 31, 2023, the amounts reported for cash, investment in affiliate, accrued interest and other expenses, notes payables, and derivative liability approximate the fair value because of their short maturities.
We adopted ASC Topic 820 for financial instruments measured as fair value on a recurring basis. ASC Topic 820 defines fair value, established a framework for measuring fair value in accordance with accounting principles generally accepted in the United States and expands disclosures about fair value measurements.
Recently Issued Accounting Pronouncements
Management reviewed currently issued pronouncements during the nine months ended March 31, 2023, and does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying condensed financial statements. Pronouncements are disclosed in notes to the financial statements.
Results of Operations for the Three Months Ended March 31, 2023 compared to Three Months Ended March 31, 2022
Operating Expenses
Operating expenses for the three months ended March 31, 2023 were $1,325,255 compared to $2,131,707 for the three months ended March 31, 2022. The net decrease of $806,452 in operating expenses consisted primarily of a decrease in noncash stock compensation expense.
Other Income/(Expenses)
Other income and (expenses) for the three months ended March 31, 2023 were $3,019,088 compared to $7,810,011 for the three months ended March 31, 2023. The decrease in other expenses of $4,790,923 was the result of a decrease in gain on change in derivative liability, and an increase in unrealized loss on investment in affiliate.
Net Income/(Loss)
For the three months ended March 31, 2023, our net income was $1,693,833, compared to net income of $5,678,304 for the three months ended March 31, 2022. The majority of the decrease in net income of $3,984,471, was related primarily to the decrease in net change of derivative instruments estimated each period. These estimates are based on multiple inputs, including the market price of our stock, interest rates, our stock price, volatility, variable conversion prices based on market prices defined in the respective agreements and probabilities of certain outcomes based on managements’ estimates. These inputs are subject to significant changes from period to period, therefore, the estimated fair value of the derivative liabilities will fluctuate from period to period, and the fluctuation may be material. The Company has not generated any revenues.
Results of Operations for the Nine Months ended March 31, 2023 compared to Nine Months Ended March 31, 2022
Operating Expenses
Operating expenses for the nine months ended March 31, 2023 were $6,977,092, compared to $3,469,084 for the nine months ended March 31, 2022. The net decrease of $3,508,008 in operating expenses consisted primarily of a decrease in salaries and research and development.
Other Income/(Expenses)
Other income and (expenses) for the nine months ended March 31, 2023 were $12,420,741, compared to $82,203,995 for the nine months ended March 31, 2022. The decrease in other expenses of $69,783,254 was the result of a decrease in the fair value change in derivative liability and the unrealized gain on investment in affiliate.
Net Income/(Loss)
For the nine months ended March 31, 2023, our net income was $5,443,649, compared to net income of $78,734,911 for the nine months ended March 31, 2022. The majority of the decrease in net income of $73,291,262 was related primarily to the decrease in net change of derivative instruments estimated each period. These estimates are based on multiple inputs, including the market price of our stock, interest rates, our stock price, volatility, variable conversion prices based on market prices defined in the respective agreements and probabilities of certain outcomes based on managements’ estimates. These inputs are subject to significant changes from period to period, therefore, the estimated fair value of the derivative liabilities will fluctuate from period to period, and the fluctuation may be material. The Company has not generated any revenues.
Liquidity and Capital Resources
Liquidity is the ability of a company to generate funds to support its current and future operations, satisfy its obligations, and otherwise operate on an ongoing basis. Significant factors in the management of liquidity are funds generated by operations, levels of accounts receivable and accounts payable and capital expenditures.
As of March 31, 2023, we had working capital of $31,963,178, compared to $24,865,577 as of June 30, 2022. This increase in working capital of $7,097,601 was primarily due to an increase in cash.
Cash used in operating activities was $3,346,769 for the nine months ended March 31, 2023, compared to $2,211,559 for the nine months ended March 31, 2022. The increase in cash used in operating activities was due to an increase in salaries and research and development. The Company has had no revenues.
Cash provided by (used in) investing activities during the nine months ended March 31, 2023 and March 31, 2022 was $3,934,306 and $(10,648,389), respectively. The increase of $14,582,695 in investing activities was due to the redemption of the securities and the purchase of assets.
Cash provided by financing activities during the nine months ended March 31, 2023 was $1,863,618, compared to cash used in financing activities of $(490,000) for the nine months ended March 31, 202. The increase in cash provided by financing activities was due to income received through the investment in securities.
Our ability to continue as a going concern is dependent upon raising capital through financing transactions and future revenue. Our capital needs have primarily been met from the proceeds of private placements and registered offerings of our securities, as we have not generated any revenues to date.
We have historically obtained funding from investors, through private placements and registered offerings of equity and debt securities. Management believes that the Company will be able to continue to raise funds through the sale of its securities to its existing shareholders and prospective new investors, which will provide the additional cash needed to meet the Company’s obligations as they become due and will allow the Company to continue to develop its core business. There can be no assurance that we will be able to continue raising the required capital for our operations on terms and conditions that are acceptable to us, or at all. If we are unable to obtain sufficient funds, we may be forced to curtail and/or cease our operation.
Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements that are reasonably likely to have a current or future effect on our financial condition, revenues or expenses, result of operations, liquidity or capital expenditures.
Controls and procedures
As filed, 1,278 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
As of the end of the period covered by this report, we conducted an evaluation, under the supervision and with the participation of our chief executive officer and chief financial officer of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) of the Exchange Act). Based upon this evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is: (i) recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms, and (ii) accumulated and communicated to our management, including our chief executive officer and chief financial officer, or person performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control Over Financial Reporting
There was no change to our internal control over financial reporting that occurred during our last fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Risk factors
As filed, 145 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
There are no material changes from the risk factors previously disclosed in our annual report on Form 10-K filed with the SEC on October 7, 2022.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2023-01-01 to 2023-03-31 | $764.9k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2022-07-01 to 2023-03-31 | $2.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2023-01-01 to 2023-03-31 | −$1.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2022-07-01 to 2023-03-31 | −$7.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2023-01-01 to 2023-03-31 | $19.6k | us-gaap:InterestExpense |
| Interest expense | 9 months2022-07-01 to 2023-03-31 | $64.6k | us-gaap:InterestExpense |
| Net income | 3 months2023-01-01 to 2023-03-31 | $1.7m | us-gaap:NetIncomeLoss |
| Net income | 9 months2022-07-01 to 2023-03-31 | $5.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-01-01 to 2023-03-31 | $0.00 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2022-07-01 to 2023-03-31 | $0.00 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-01-01 to 2023-03-31 | $0.00 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2022-07-01 to 2023-03-31 | $0.00 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-01-01 to 2023-03-31 | 5,536,927,470 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2022-07-01 to 2023-03-31 | 5,392,419,929 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2022-07-01 to 2023-03-31 | −$3.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2022-07-01 to 2023-03-31 | $33.8k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2023-03-31 | $30.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-03-31 | $52.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-03-31 | $55.2m | us-gaap:Assets |
| Current liabilities | At period end2023-03-31 | $20.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-03-31 | $20.2m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-03-31 | $34.7m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001213900-23-039766. Last ingested by Listed: Oct 26, 2026, 16:02 ET. Listed shows no prices and gives no investment advice.